Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

748.01 -1.91 (-0.25%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Eli Lilly Sues Some Vendors For Unauthorized Sale Of Fake Weight-Loss Drug
Eli Lilly sues vendors for selling unauthorized tirzepatide amid resolved shortages. Lawsuits target vendors offering counterfeit versions of Zepbound and Mounjaro 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
1 Reason to Buy Eli Lilly Stock Hand Over Fist Right Now
Eli Lilly just secured a huge win, and it's not related to the weight loss industry. 
Via The Motley Fool
Investing $10,000 in Each of These 3 Stocks 10 Years Ago Would Have Made You $1.1 Million
These hot growth stocks may not be running out of steam just yet. 
Via The Motley Fool
AskSlim Market Week - Friday, Oct. 19
An analysis and commentary on the financial markets. 
Via Talk Markets
Behind the Scenes of Eli Lilly's Latest Options Trends
Via Benzinga
Investigating Eli Lilly's Standing In Pharmaceuticals Industry Compared To Competitors
Via Benzinga
$1000 Invested In Eli Lilly 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Exploring NYSE:LLY's high growth characteristics.
Delving into ELI LILLY & CO (NYSE:LLY)'s high Growth Prospects. 
Via Chartmill
Eli Lilly Unusual Options Activity
Via Benzinga
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
Via Investor's Business Daily
2 High-Flying Growth Stocks With Massive Upside Potential
These innovative drugmakers have potential catalysts ahead. 
Via The Motley Fool
This is Huge News For Eli Lilly Investors
Eli Lilly is investing billions into new research and manufacturing capabilities. 
Via The Motley Fool
3 Reasons Eli Lilly Stock Isn't Going to Run out of Steam Anytime Soon
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate. 
Via The Motley Fool
Hims & Hers Shares Have Rallied 22% This Week. Why That Move Is Now At Risk.
Hims & Hers has enjoyed a rally on an FDA decision regarding Eli Lilly's tirzepatide. 
Via Investor's Business Daily
Exposures Product Safety
This Artificial Intelligence Move Is One New Reason to Buy Eli Lilly Stock in 2024
Lilly is staying ahead of the technology curve instead of falling behind. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
These are two of healthcare's biggest darlings right now, but one looks better positioned for the long run. 
Via The Motley Fool
Should Eli Lilly Investors Worry About This Unexpected FDA Move?
Lilly has invested billions of dollars to ramp up production capacity. 
Via The Motley Fool
Exposures Product Safety
Jim Cramer: 'We Need More Uranium,' Recommends This Stock; Says Novo Nordisk 'Doesn't Hold A Candle' To Big Pharma Rival
Jim Cramer believes Uranium Energy Corp. is going higher, thanks to a recent acquisition deal. Novo Nordisk faces antitrust concerns while Halliburton gets a Buy rating from BofA Securities. 
Via Benzinga
Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce
Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana. 
Via Talk Markets
Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe
Eli Lilly invests £279M in the UK to boost life sciences, while its Alzheimer's drug, donanemab, faces European regulatory hurdles amid ongoing trials and safety concerns. 
Via Benzinga
Hims & Hers Health Stock Is Popping Monday: What's Behind The Move?
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday after the U.S. Food and Drug Administration said it would reconsider a decision barring drug compounders from selling their own... 
Via Benzinga
Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug
An industry group sued the FDA, claiming tirzepatide remains in shortage. 
Via Investor's Business Daily
Topics Lawsuit
Exposures Financial Legal Product Safety
More Patients On Eli Lilly's Mirikizumab Achieved Histologic Response At One Year Compared To Johnson & Johnson's Drug
On Monday, Eli Lilly And Co (NYSE:LLY) announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of mirikizumab compared with a placebo and active control (Johnson & Johnson’s... 
Via Benzinga
'Most Widely Hated' Bull Market Reaches 2-Year Milestone: Top 20 S&P 500 Stocks Driving The Rally
S&P 500 bull market defies expectations with 63% gains in 2 years, led by technology sector. Top performers include Nvidia, Super Micro Computer, and Vistra Corp. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
The analyst is closely watching MariTide, a potential monthly injection to treat obesity. 
Via Investor's Business Daily
Which Pharma Stock Is the Better Bargain Buy: Pfizer or Eli Lilly?
These two stocks will appeal to very different types of investors at the moment. 
Via The Motley Fool
FDA To Reassess Ban On Cheaper, Compounded Versions of Eli Lilly Weight Loss Drugs
The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, sparking legal and industry pushback. 
Via Benzinga
Exposures Product Safety
3 No-Brainer Growth Stocks to Buy in October
These stocks look like slam-dunk picks for growth investors. 
Via The Motley Fool
Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
Eli Lilly is the most valuable pharmaceutical company in the world. I believe the company has what it takes to stay there. 
Via MarketBeat
Got $500? 2 Magnificent Growth Stocks to Buy and Hold Forever
These industry leaders still look like top-notch buys. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.